+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID06314087

Phase II Study of Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy for Advanced Solid Tumors

Led by The University of Hong Kong-Shenzhen Hospital · Updated on 2025-03-25

154

Participants Needed

2

Research Sites

2 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an individualized tumor neoantigen peptide vaccine combined with radiotherapy in patients with advanced malignant solid tumors that have not responded to standard treatments or have progressed. This Phase II randomized study aims to observe tumor burden after treatment, immune responses triggered by the vaccine, and overall patient survival to assess the vaccines safety and effectiveness alongside radiotherapy. The treatment involves collecting tumor tissue surgically or by biopsy and blood samples to analyze tumor gene mutations and confirm mutation expression. Using advanced sequencing and software analysis, personalized neoantigen peptides are identified and synthesized into a vaccine. Participants first receive precise radiotherapy, followed one week later by the peptide vaccine treatment lasting up to five months. The study includes two groups one receiving the personalized vaccine plus conventional radiotherapy and the other receiving placebo plus conventional radiotherapy. Participants will undergo assessments including imaging to measure tumor lesions and monitor progression-free survival at the end of each treatment course and at several intervals up to four months after treatment completion. Safety, feasibility, and immune response are evaluated throughout. Eligibility involves meeting criteria related to tumor status, survival expectancy, and ability to provide tumor DNA samples. The total study duration includes treatment and follow-up visits to track outcomes and patient health.

CONDITIONS

Brief Title

Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)

Research Team

F

Feng-Ming (Spring) Kong

Y

Yan Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here